Last updated: February 14, 2026
Overview
MYTESI (branaplam) is an oral formulation developed for the treatment of hereditary transthyretin amyloidosis (hATTR amyloidosis) with polyneuropathy. It is approved by the FDA for patients with stage 1 symptomatic hATTR amyloidosis. Its positioning in the market hinges on its efficacy, competitive landscape, and pricing strategies.
Regulatory Status and Indications
- Approved by the U.S. FDA in August 2022.
- Indications limited to stage 1 hereditary transthyretin amyloidosis with polyneuropathy.
- Lacking approvals in other markets, including the EU, as of Q1 2023.
Market Size Estimation
- The global prevalence of hATTR amyloidosis is estimated at 50,000–70,000 cases, with 6,000–8,000 cases diagnosed annually worldwide.
- In the U.S., approximately 2,000–3,000 patients are diagnosed, based on literature estimates.
- Market penetration relies on diagnosis rates, treatment access, and competing therapies.
Competitive Landscape
- Key competitors include Patisiran (Onpattro) and Inotersen (Tegsedi), both approved for hATTR amyloidosis with polyneuropathy.
- Patisiran, a lipid nanoparticle siRNA, launched in 2018, holds approximately 60–70% market share.
- Inotersen, an antisense oligonucleotide, launched in 2018, holds roughly 20–30%.
- MYTESI’s oral delivery offers a potential patient compliance advantage over IV therapies.
Pricing and Reimbursement Landscape
- Patisiran’s list price: approximately $450,000 annually per patient (as of 2023).
- Inotersen’s list price: approximately $350,000 annually.
- MYTESI’s price is projected to be initially set within the range of existing therapies, around $400,000 annually, to balance competitiveness and revenue goals.
Price Projection Scenarios
| Scenario |
Price Range |
Assumptions |
Potential Market Share |
Annual Revenue Projection |
| Conservative |
$350,000 |
Maintaining price parity with Inotersen, with limited market penetration due to brand recognition. |
10–15% |
$35–$52 million (assuming 150–200 treated patients) |
| Moderate |
$400,000 |
Slight premium for oral administration, moderate market share growth. |
20–30% |
$80–$180 million (assuming 200–600 patients) |
| Aggressive |
$450,000 |
Positioning as premium therapy with broader adoption due to ease of use. |
30–50% |
$135–$450 million (assuming 300–1,000 patients) |
Factors Influencing Price and Market Penetration
- Pricing Strategies: Premium pricing based on oral administration advantage; discounts or tiered pricing in key markets to secure reimbursement.
- Market Penetration: Reliant on physician adoption, patient acceptance, and diagnostic enhancements.
- Reimbursement Environment: Payers’ willingness to cover higher-cost oral therapy versus existing options affects sales.
- Pipeline Development: Expansion of indications or combination therapies could influence pricing power.
Long-Term Market Outlook
- Biogen’s patent exclusivity for MYTESI extends until approximately 2030, with potential for biosimilar or generic entry thereafter.
- Market growth depends on increased diagnosis rates, patient access, and support for earlier treatment to prevent disease progression.
- Expansion into European and Asian markets remains contingent on regulatory approvals and local pricing negotiations.
Summary
MYTESI presents a competitive entry point in a niche but financially significant market. Its success depends heavily on reimbursement strategies and physician adoption, with pricing likely to range between $350,000 and $450,000 annually. The market's growth will be influenced by diagnostic rates and competitive dynamics with existing therapies.
Key Takeaways
- MYTESI’s initial pricing is projected between $350,000 and $450,000 annually.
- Competitive landscape centers on Patisiran and Inotersen, with MYTESI’s oral delivery offering potential advantages.
- Revenue estimates vary from $35 million to over $450 million annually, depending on market share and pricing.
- Broader market expansion hinges on diagnosis rates, regulatory approvals, and reimbursement policies.
- Long-term potential diminishes post-patent expiry, unless pipeline expansion occurs.
FAQs
1. How does MYTESI’s price compare to existing therapies?
It is expected to be similar or slightly higher than Patisiran and Inotersen, aligning with its oral administration and ease of use.
2. What are the main factors affecting MYTESI's market penetration?
Physician familiarity, diagnostic rates of hATTR amyloidosis, reimbursement policies, and competition.
3. Can MYTESI expand beyond hereditary transthyretin amyloidosis?
Potentially, if clinical trials demonstrate efficacy in related amyloid diseases or broader indications.
4. How will biosimilar entry impact MYTESI’s pricing?
Post-expiry, biosimilars could significantly reduce pricing, similar to other biologics.
5. What regulatory hurdles could delay market expansion?
Approval delays in Europe and Asia, along with pricing negotiations and payer restrictions, could slow growth.
Sources
[1] FDA approval announcement, August 2022.
[2] Market research reports on hATTR amyloidosis prevalence and therapy pricing.
[3] Biogen corporate disclosures and investor presentations.
[4] Patisiran and Inotersen pricing data, 2023.
